Skip to content
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Menu
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Happy News

The FDA Fast-Tracked Psychedelic Medicines For Depression And PTSD

The Food and Drug Administration has fast-tracked three psychedelic medicines for review, issuing priority vouchers to companies studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone, a compound related to MDMA, for post-traumatic stress disorder, in a development that could put the first FDA-approved psychedelic medicines on the market as soon as this summer. The vouchers compress the agency’s standard review timeline from the usual 10 to 12 months down to just one to two months, a change the FDA Commissioner said is designed to ensure that red tape does not delay treatments that show genuine promise for conditions that have been notoriously difficult to treat. The three companies that received vouchers are Compass Pathways, the nonprofit Usona Institute, and Otsuka Pharmaceutical, which is acquiring the methylone program. The action followed an executive order signed by President Trump directing the FDA to prioritize psychedelic drugs that have received Breakthrough Therapy designation, a status reserved for treatments showing early evidence of substantial improvement over existing options.

For millions of Americans with treatment-resistant depression, PTSD, and other serious mental health conditions that have not responded to available medications, the move represents a potential turning point in access to a category of medicine that has shown significant clinical results but has remained largely inaccessible for decades. Psilocybin has shown durable antidepressant effects in multiple studies, with some patients maintaining improvement for at least a year after a single treatment course. The FDA also cleared the first-ever clinical study in the United States of noribogaine, a compound derived from the ibogaine plant, as a potential treatment for alcohol use disorder, a condition that affects more than 29 million Americans. The FDA Commissioner said the first psychedelic drug could receive approval by the end of summer, and that the field is moving forward grounded in sound science and rigorous clinical standards.

Source: https://edition.cnn.com/2026/04/24/health/fda-psychedelic-drugs-priority-vouchers

PrevPreviousJurassic Park Star Sam Neill Is Cancer Free
NextBanksy Just Confirmed His Latest Masterpiece, And London Is Already Crowding Around ItNext

Recent Articles

Happy News

Scientists Just Proved That Your Brain Can Dream While You Are Wide Awake

May 11, 2026

A study from the Paris Brain Institute, published in Cell Reports, has overturned something most people take for granted: that dreaming and waking are two cleanly separate mental states, each with their own type of thoughts. Researchers monitored 92 adults using EEG caps as they drifted into and out of

Read More
Happy News

A Kitten Found Covered Head To Tail In Industrial Glue Just Made A Full Recovery And Has A New Home

May 11, 2026

When a good Samaritan in Fort Worth, Texas, discovered a small kitten stuck in a bucket of industrial-strength glue near an industrial area in April and rushed him to the Humane Society of North Texas, shelter staff were not sure the tiny animal would survive the night. The glue was

Read More
Happy News

The FDA Just Gave Pancreatic Cancer Patients Early Access To A Pill That Doubled Survival Time

May 11, 2026

The Food and Drug Administration has authorized early expanded access to a new pill called daraxonrasib, developed by Revolution Medicines, giving patients with advanced pancreatic cancer a chance to receive the experimental treatment while it awaits full regulatory approval, in a move the agency completed just two days after receiving

Read More
« Previous Next »
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
Copyright © 2026 HappyNews.